influenza
viru
iav
major
caus
respiratori
ill
given
diseas
sever
associ
econom
cost
recent
appear
novel
iav
strain
renew
interest
develop
novel
efficaci
univers
iav
vaccin
strategi
recent
studi
highlight
immun
capabl
gener
local
ie
nasal
mucosa
lung
tissueresid
memori
b
cell
addit
system
immun
offer
greatest
protect
futur
iav
encount
current
iav
vaccin
design
larg
stimul
iavspecif
antibodi
gener
lungresid
memori
b
cell
induc
iav
infect
herein
report
intranas
administ
biocompat
polyanhydrid
nanoparticlebas
iav
vaccin
iavnanovax
capabl
provid
protect
subsequ
homolog
heterolog
iav
infect
inbr
outbr
popul
find
also
demonstr
vaccin
iavnanovax
promot
induct
germin
center
b
cell
within
lung
system
lung
local
iavspecif
antibodi
iavspecif
lungresid
memori
cell
altogeth
find
show
intranas
administ
nanovaccin
induc
immun
within
lung
similar
occur
iav
infect
thu
could
prove
use
strategi
provid
univers
protect
iav
influenza
viru
iav
common
respiratori
pathogen
undergo
season
antigen
drift
continu
give
rise
variant
strain
escap
exist
immun
protect
viral
drift
detriment
impact
public
health
well
economi
within
unit
state
exemplifi
hospit
death
milliondollar
financi
burden
observ
season
tradit
spread
iav
prevent
two
vaccin
strategi
inactiv
influenza
vaccin
iiv
liveattenu
influenza
vaccin
laiv
iiv
laiv
primarili
provid
system
immun
induc
iavspecif
antibodi
respons
howev
less
clear
vaccin
strategi
gener
robust
de
novo
iavspecif
cell
respons
within
lower
lung
mucosa
due
intramuscular
deliveri
iiv
thought
drive
airwayresid
effector
cell
respons
although
laiv
shown
induc
cell
respons
within
lung
mice
follow
whole
lung
inocul
laiv
vaccin
limit
upper
respiratori
tract
anim
model
similar
replic
locat
human
induc
cell
respons
within
lower
lung
mucosa
mani
recent
effort
univers
vaccin
focus
target
antibodi
respons
toward
conserv
stem
region
hemagglutinin
ha
iav
protein
howev
infectioninduc
immun
also
confer
protect
underli
cell
respons
provid
crossstrain
protect
cellmedi
heterosubtyp
protect
well
describ
anim
model
shown
confer
increas
protect
human
recent
pandem
furthermor
studi
anim
model
iav
infect
demonstr
pulmonari
immun
system
imprint
effector
cell
lung
home
capabl
well
induc
format
local
tissueresid
memori
b
cell
thought
provid
optim
protect
tissueresid
phenotyp
thought
depend
antigen
longev
antigen
present
cell
apc
tertiari
structur
within
tissu
therefor
vaccin
util
tissuespecif
factor
pathway
critic
induct
pulmonari
b
cell
respons
gener
local
well
system
immun
mimick
iav
infect
would
predict
confer
robust
protect
previous
report
novel
polyanhydrid
copolym
pcarboxyphenoxi
cpteg
pcarboxyphenoxi
hexan
cph
nanoparticlebas
vaccin
platform
shown
great
promis
induc
immun
administ
subcutan
sc
platform
offer
sever
distinct
advantag
particl
degrad
biocompat
product
activ
apc
maintain
stabil
encapsul
antigen
enabl
dose
spare
antigen
may
store
room
temperatur
higher
month
thu
break
cold
chain
anoth
import
featur
nanoparticl
technolog
provid
sustain
releas
encapsul
antigen
via
surfac
eros
act
longterm
antigen
depot
therefor
could
mimic
antigen
depot
occur
iav
infect
potenti
tissueresid
memori
format
howev
capabl
intranas
administr
polyanhydrid
nanoparticl
induc
local
ie
lung
system
adapt
immun
drive
tissueresid
memori
format
offer
crossstrain
protect
iav
yet
explor
end
test
immun
capabl
administ
cpteg
cph
polyanhydrid
nanovaccin
contain
ha
nucleocapsid
protein
np
protein
strain
apuerto
iav
cpg
hereaft
refer
iavnanovax
result
illustr
vaccin
iavnanovax
induc
robust
lungresid
germin
center
gc
b
cell
along
system
lung
local
iavspecif
antibodi
respons
notabl
similar
iav
infect
administ
iavnanovax
induc
lungresid
memori
cell
respons
iavspecif
humor
cellular
immun
respons
associ
protect
homolog
heterolog
infect
vaccin
mice
protect
subsequ
lethal
dose
challeng
strain
iav
respect
monom
base
pcarboxyphenoxi
cpteg
pcarboxyphenoxi
hexan
cph
synthes
describ
previous
use
monom
cpteg
cph
copolym
synthes
use
melt
polycondens
h
describ
final
copolym
composit
puriti
molecular
weight
copolym
character
use
h
hnmr
dxr
bruker
billerica
next
cpteg
cph
nanoparticl
contain
ha
np
synthes
via
solidoiloil
doubl
emuls
briefli
ha
np
protein
antigen
sino
biolog
beij
china
dialyz
nanopur
water
lyophil
overnight
cpteg
cph
copolym
along
ha
np
cpg
odn
invivogen
san
diego
ca
dissolv
polym
concentr
mgml
methylen
chlorid
solut
sonic
precipit
chill
pentan
methylen
chlorid
pentan
ration
result
nanoparticl
collect
via
vacuum
filtrat
scan
electron
microscopi
fei
quanta
fei
hillsboro
use
character
morpholog
size
wild
type
femal
mice
bred
hous
maintain
univers
iowa
iowa
citi
ia
anim
care
facil
swisswebst
mice
nci
cr
swweb
purchas
charl
river
laboratori
inc
frederick
md
maintain
univers
iowa
iowa
citi
ia
anim
care
facil
procedur
perform
match
mice
approv
institut
anim
care
use
committe
univers
iowa
compli
nih
guid
care
use
laboratori
anim
mice
randomli
assign
group
experi
prior
iavnanovax
vaccin
iav
infect
mice
anesthet
isofluran
iavnanovax
administr
mice
receiv
iavnanovax
contain
total
ha
np
pb
contain
free
ha
np
protein
primeboost
experi
mice
receiv
second
dose
iavnanovax
day
initi
iavnanovax
prime
experi
util
iavnanovax
vaccin
without
free
antigen
compon
mice
receiv
iavnanovax
contain
total
ha
np
pb
follow
second
dose
iavnanovax
without
free
antigen
day
initi
iavnanovax
prime
experi
util
vaccin
polyanhydrid
particl
contain
cpg
particl
mice
receiv
cpg
particl
pb
iav
infect
mice
infect
tciu
tciu
dose
mous
adapt
apuerto
rico
enhanc
paus
penh
indic
lung
function
ie
airway
resist
measur
use
unrestrain
wholebodi
plethysmographi
buxco
electron
wilmington
nc
nonanesthet
mice
previous
describ
penh
valu
record
daili
base
volum
pressur
chang
min
lung
viral
titer
analyz
plaqu
assay
whole
lung
homogen
briefli
serial
dilut
homogen
lung
sampl
appli
confluent
madindarbi
canin
kidney
epitheli
cell
layer
incub
h
c
cell
layer
wash
minimum
essenti
media
agar
overlay
appli
incub
day
c
cell
layer
fix
formaldehyd
block
milk
plaqu
detect
polyclon
antiiav
apuerto
chicken
antiserum
bei
resourc
peroxidaseconjug
affinipur
rabbit
antichicken
igi
jackson
immunoresearch
west
grove
pa
trueblu
r
peroxidas
substrat
kpl
gaithersburg
md
three
minut
prior
euthanasia
mice
administ
fluorophoreconjug
rat
antimous
clone
biolegend
san
diego
ca
pb
retroorbit
intraven
inject
previous
describ
prior
euthanasia
blood
collect
heparin
capillari
tube
fisher
scientif
pittsburgh
pa
subsequ
singlecel
analysi
flow
cytometri
nonheparin
capillari
tube
fisher
scientif
serum
collect
cell
harvest
blood
sampl
treat
ammoniumchloridepotassium
lysi
buffer
min
room
temperatur
wash
flow
cytometri
stain
buffer
serum
collect
blood
sampl
left
room
temperatur
min
centrifug
g
min
collect
store
c
analysi
bronchial
alveolar
lavag
bal
fluid
collect
use
protocol
modifi
briefli
trachea
cannul
cathet
tube
attach
syring
wash
ml
steril
pb
sampl
store
c
analysi
prepar
cell
lung
spleen
organ
harvest
collect
bal
fluid
digest
min
c
media
contain
mgml
collagenas
type
mp
biomed
solon
oh
mgml
dnasei
mp
biomed
press
wire
mesh
obtain
singl
cell
suspens
total
iavspecif
igg
iga
antibodi
whole
apuerto
live
viru
measur
previous
describ
briefli
well
coat
tciu
viru
block
bovin
serum
albumin
wash
blot
dri
serum
bal
sampl
ad
top
well
triplic
dilut
respect
sampl
serial
dilut
incub
c
h
plate
wash
blot
dri
iavspecif
antibodi
detect
use
follow
antibodi
biotinlabel
goat
antimous
iga
southern
biotechnolog
associ
birmingham
al
biotinlabel
affinipur
goat
antimous
igg
fc
fragment
specif
jackson
immunoresearch
laboratori
follow
alkalin
phosphatasestreptavidin
invitrogen
carlsbad
ca
mgml
phosphatas
substrat
sigmaaldrich
st
loui
mo
optic
densiti
measur
nm
use
spectramax
multimod
micropl
reader
molecular
devic
sunnyval
ca
hemagglutin
inhibit
hai
assay
use
mous
serum
bal
perform
previous
describ
briefli
sera
bal
inactiv
heat
c
min
absorb
chicken
red
blood
cell
crbc
suspens
min
differ
concentr
serum
absorb
cbrc
bal
absorb
cbrc
cbrc
pellet
sera
bal
serial
dilut
roundbottom
plate
incub
four
hemagglutin
unit
stock
viru
per
well
min
well
receiv
cbrc
suspens
hai
titer
measur
min
incub
singlecel
suspens
cell
lung
block
rat
serum
min
c
follow
block
cell
stain
follow
antibodi
rat
antimous
biolegend
rat
antimous
biolegend
rat
antimous
biolegend
rat
antimous
bd
bioscienc
san
jose
ca
rat
antimous
bd
bioscienc
rat
antimous
ebiosci
identifi
cell
subset
antigen
experienc
cell
identifi
via
express
surrog
marker
previous
describ
briefli
hi
po
express
util
identifi
antigenexperienc
cell
hi
lo
express
util
quantifi
antigenexperienc
cell
identifi
b
cell
subset
cell
stain
rat
antimous
bd
bioscienc
rat
antimous
biolegend
rat
antimous
igm
fitcconjug
peanut
agglutinin
pna
vector
laboratori
burlingam
ca
cell
fix
bd
fac
tm
lyse
solut
per
manufactur
instruct
resuspend
pb
data
acquir
lsrii
bd
bioscienc
analyz
use
flowjo
softwar
tree
star
ashland
experi
repeat
least
twice
unless
note
otherwis
comparison
two
group
perform
twotail
student
ttest
comparison
two
group
differ
time
point
analyz
use
twoway
anova
holmsidak
multipl
comparison
posthoc
test
comparison
two
group
singl
time
point
dagostino
pearson
normal
test
perform
establish
normal
data
fail
normalci
analyz
use
kruskalw
anova
dunn
multipl
comparison
posthoc
test
data
pass
normalci
analyz
use
oneway
anova
tukey
multipl
comparison
posthoc
test
p
consid
signific
order
design
iav
vaccin
provid
optim
protect
induc
longliv
local
ie
lung
system
immun
respons
made
use
cpteg
cph
polyanhydrid
nanovaccin
platform
previou
studi
shown
cpteg
cph
copolymerbas
nanoparticl
formul
effect
deliveri
vehicl
iav
antigen
gener
system
immun
respons
given
sc
therefor
order
gener
lungfocus
well
system
immun
design
vaccin
iavnanovax
consist
cpteg
cph
nanoparticl
encapsul
iav
ha
np
protein
sourc
apuerto
along
cpg
oligo
odn
known
induc
crosspresent
dendrit
cell
ha
protein
includ
primari
compon
current
vaccin
strategi
focu
neutral
antibodi
respons
addit
np
protein
incorpor
shown
drive
npspecif
cell
respons
provid
protect
heterolog
infect
well
induc
nonneutr
antibodi
respons
facilit
rapid
cell
respons
upon
subsequ
exposur
nanoparticl
administ
water
along
free
ha
np
protein
primeboost
regimen
previou
work
laboratori
shown
addit
solubl
antigen
togeth
nanovaccin
primeboost
vaccin
enhanc
immun
respons
protect
follow
subcutan
vaccin
sinc
gener
iavspecif
antibodi
respons
frequent
use
determin
iav
vaccin
efficaci
began
analyz
b
cell
respons
lung
follow
iavnanovax
vaccin
compar
respons
mice
infect
iav
mice
im
vaccin
iiv
mice
left
untreat
order
distinguish
lymphocyt
embed
lung
interstitium
vasculatur
util
vivo
fluorophoreconjug
antibodi
label
techniqu
supplement
data
sheet
end
mice
intravascularli
iv
infus
prior
lung
harvest
fluoresc
antibodi
label
b
cell
within
circul
po
vs
lung
parenchyma
neg
supplement
data
sheet
use
techniqu
observ
total
lungresid
b
cell
po
po
neg
significantli
higher
iavinfect
iavnanovax
vaccin
mice
compar
iiv
control
day
follow
infectionvaccin
figur
consist
increas
total
number
iavinfect
iavnanovax
treat
mice
lungresid
gc
b
cell
po
po
neg
pna
po
also
significantli
elev
time
point
figur
e
supplement
data
sheet
similar
trend
also
observ
lung
drain
lymph
node
data
shown
gc
b
cell
reaction
result
classswitch
b
cell
produc
higher
affin
antibodi
next
compar
frequenc
igm
neg
lungresid
gc
b
cell
iavinfect
iavnanovax
treat
mice
previous
shown
iav
infect
induc
substanti
proport
gc
respons
lung
switch
igg
igm
neg
igg
po
similar
iavinfect
mice
approxim
lung
resid
gc
b
cell
igm
neg
iavnanovax
mice
find
consist
robust
matur
gc
respons
figur
f
result
suggest
administr
iavnanovax
induc
lungresid
gc
b
cell
respons
capabl
produc
classswitch
b
cell
level
commensur
found
iavinfect
mice
day
follow
infectionvaccin
determin
observ
b
cell
respons
gener
iavspecif
antibodi
quantifi
total
iavspecif
igg
iga
antibodi
follow
infect
vaccin
expect
iavspecif
igg
respons
detect
local
ie
bronchoalveolar
lavag
bal
system
ie
serum
iavinfect
iavnanovax
vaccin
mice
day
follow
infectionvaccin
figur
b
e
interestingli
serum
level
iavspecif
igg
antibodi
higher
anim
iavnanovax
iav
infect
mice
receiv
iiv
figur
mice
receiv
iiv
also
lack
robust
iavspecif
igg
within
bal
observ
iavnanovax
iav
infect
mice
figur
e
differ
measur
iavspecif
igg
within
bal
iiv
iavnanovax
like
relat
lack
local
lung
gc
respons
iiv
vaccin
mice
figur
previou
studi
demonstr
iga
present
bal
iav
infect
consist
idea
found
iavinfect
iavnanovax
iiv
induc
iavspecif
iga
level
bal
figur
f
determin
potenti
iavspecif
antibodi
contribut
protect
lethal
dose
iav
infect
measur
capabl
serum
bal
antibodi
inhibit
iavhemagglutin
day
post
infectionvaccin
iiv
iavnanovax
vaccin
mice
serum
hemagglutin
inhibit
hai
titer
similar
iav
infect
mice
well
mark
associ
protect
subsequ
iav
infect
figur
howev
iav
infect
iavnanovax
vaccin
mice
possess
protect
level
hai
antibodi
within
bal
figur
altogeth
result
suggest
administr
iavnanovax
induc
local
system
iavspecif
antibodi
respons
capabl
provid
protect
iav
infect
gener
gc
b
cell
respons
classswitch
antibodi
often
associ
antigenspecif
cell
respons
also
shown
iavspecif
cell
import
control
iav
therefor
determin
capac
iavnanovax
elicit
iavspecif
cell
respons
within
lung
cell
respons
iav
shown
encompass
larg
number
epitop
express
low
frequenc
thu
order
bia
respons
examin
singl
epitop
specif
util
surrog
marker
stain
strategi
strategi
identifi
total
antigenexperienc
cell
figur
b
includ
epitop
identifi
limit
compar
mice
iav
infect
iavnanovax
vaccin
gener
increas
frequenc
antigenexperienc
cell
agexp
po
hi
po
antigenexperienc
cell
agexp
lo
hi
within
lung
day
figur
b
observ
vast
major
agexp
agexp
cell
resid
within
lung
tissu
neg
base
vivo
antibodi
label
iavnanovax
vaccin
mice
similar
observ
follow
iavinfect
figur
b
importantli
lungresid
agexp
cell
iavnanovax
vaccin
mice
found
higher
number
compar
iiv
vaccin
mice
day
post
vaccin
figur
although
number
lungresid
agexp
cell
higher
earli
day
iavinfect
mice
compar
iavnanovax
mice
figur
f
iavnanovax
capabl
induc
cell
respons
similar
magnitud
observ
iav
infect
lung
later
time
point
figur
e
g
h
figur
iavnanovax
vaccin
induc
lung
system
iavspecif
antibodi
respons
mice
vaccinatedinfect
describ
figur
day
post
challengevaccin
serum
bal
collect
total
iavspecif
serum
igg
bal
igg
b
e
bal
iga
c
f
quantifi
elisa
serum
g
bal
e
hai
level
quantifi
error
bar
mean
sem
lod
limit
detect
data
repres
three
independ
ac
g
two
independ
df
h
experi
n
micegroup
iav
vs
p
p
p
p
nanovax
vs
iiv
vs
p
p
twoway
anova
holmsidak
multipl
comparison
test
recent
studi
demonstr
presenc
lungresid
memori
cell
iav
infect
increas
protect
therefor
next
determin
whether
robust
lungresid
agexp
cell
respons
gener
iavnanovax
vaccin
share
phenotyp
characterist
canon
lungresid
memori
cell
trm
iavinfect
lung
express
promin
lungresid
ie
neg
agexp
cell
day
follow
iav
infect
chang
associ
establish
lungresid
memori
cell
figur
trend
also
observ
iavnanovax
vaccin
mice
howev
iavnanovax
induc
greater
fraction
canon
po
agexp
trm
cell
well
subset
coexpress
figur
c
nevertheless
po
po
po
neg
lungresid
agexp
cell
subset
elev
iavnanovax
iiv
vaccin
mice
level
equal
higher
observ
iavinfect
mice
figur
contrast
lung
trm
cell
lung
trm
cell
report
coexpress
day
follow
iavinfect
iavnanovax
vaccin
fraction
number
po
po
agexp
cell
resid
within
lung
significantli
increas
rel
iiv
vaccin
mice
figur
albeit
number
trm
initi
higher
iavinfect
mice
iavnanovax
vaccin
mice
exhibit
similar
trm
respons
iavinfect
mice
day
post
infectionvaccin
figur
overal
data
suggest
iavnanovax
vaccin
induc
trm
respons
similar
magnitud
iav
infect
given
robust
pulmonari
b
cell
respons
observ
follow
iavnanovax
vaccin
next
determin
potenti
iavnanovax
circumv
iav
associ
morbid
mortal
upon
subsequ
exposur
sinc
iavnanovax
induc
pulmonari
cell
respons
within
lung
day
post
vaccin
ie
prior
boost
figur
addit
compar
protect
prime
vs
primeboost
vaccin
schedul
fortyf
day
initi
vaccin
mice
challeng
lethal
dose
homolog
iav
apuerto
expect
mice
display
substanti
diseas
associ
weightloss
mortal
respiratori
distress
measur
increas
airway
resist
penh
howev
mice
receiv
either
prime
primeboost
iavnanovax
administr
exhibit
reduc
sign
morbid
complet
protect
mortal
figur
allevi
diseas
commensur
iiv
vaccin
mice
similar
trend
reduc
morbid
mortal
also
observ
iiv
primeboost
vaccin
mice
compar
supplement
data
sheet
strikingli
iavnanovax
primeboost
mice
exhibit
littl
weight
loss
increas
penh
demonstr
strategi
provid
robust
protect
compar
prime
mice
figur
c
consist
diseas
amelior
iavnanovax
primeboost
mice
significantli
reduc
lung
viral
titer
day
follow
challeng
indic
earli
control
viral
replic
supplement
data
sheet
sinc
iavnanovax
gener
robust
trm
respons
recent
studi
emphas
import
lungresid
memori
cell
provid
protect
subsequ
heterolog
iav
infect
next
determin
iavnanovax
vaccin
could
confer
protect
heterolog
iav
challeng
end
prime
primeboost
iavnanovax
vaccin
mice
challeng
lethal
dose
mouseadapt
heterolog
strain
iav
ahong
earli
day
follow
challeng
iavnanovax
vaccin
mice
show
similar
level
weightloss
reduc
respiratori
distress
penh
compar
mice
figur
f
furthermor
mice
succumb
highli
stringent
iav
challeng
prime
primeboost
iavnanovax
mice
protect
mortal
figur
addit
protect
mediat
iavnanovax
appear
durabl
protect
still
observ
mice
challeng
homolog
heterolog
viru
day
post
vaccin
figur
abil
iavnanovax
confer
protect
heterolog
viru
challeng
like
due
local
lung
adapt
immun
respons
induc
iavnanovax
iiv
vaccin
mice
lack
lung
trm
figur
limit
protect
heterolog
challeng
supplement
data
sheet
furthermor
protect
figur
iavnanovax
confer
protect
subsequ
homolog
heterolog
iav
infect
mice
receiv
onedos
iavnanovax
prime
twodos
iavnanovax
primeboost
left
unvaccin
naiv
fortyf
day
follow
initi
vaccin
mice
challeng
ac
tciu
dose
apuerto
df
tciu
dose
ahong
morbid
mortal
measur
daili
weight
loss
surviv
b
e
c
f
penh
record
daili
measur
lung
function
airway
resist
error
bar
mean
sem
data
repres
two
independ
c
f
three
independ
b
e
experi
n
micegroup
c
f
nanovax
primeboost
vs
p
p
p
p
nanovax
prime
vs
nanovax
vs
iav
p
p
p
twoway
anova
holmsidak
multiplecomparison
test
b
e
p
mantelcox
log
rank
test
appear
requir
adapt
immun
specif
influenza
mice
vaccin
polyanhydrid
particl
contain
cpg
iav
protein
cpg
particl
show
pulmonari
b
cell
respons
supplement
data
sheet
protect
upon
subsequ
viral
challeng
data
shown
overal
data
suggest
iavnanovax
induc
longliv
adapt
immun
respons
may
confer
signific
protect
subsequ
homolog
heterolog
iav
exposur
previous
describ
includ
free
antigen
compon
vaccin
prior
result
sc
vaccin
demonstr
inclus
free
antigen
compon
enhanc
immun
respons
protect
order
determin
free
antigen
compon
likewis
requir
n
vaccin
next
compar
immun
respons
protect
mice
vaccin
iavnanovax
free
iav
antigen
shown
supplement
data
sheet
immun
respons
lung
examin
day
post
vaccin
lungresid
b
cell
number
gc
b
cell
number
fraction
classswitch
gc
b
cell
number
lungresid
antigenexperienc
well
trm
cell
equival
increas
free
antigen
compon
administ
part
vaccin
likewis
iavspecif
igg
antibodi
titer
serum
similar
final
differ
observ
abil
vaccin
confer
protect
subsequ
lethal
dose
homolog
iav
challeng
iavnanovax
vaccin
administ
without
free
antigen
compon
compar
altogeth
result
suggest
free
antigen
compon
requir
iavnanovax
vaccin
gener
robust
immun
protect
result
present
demonstr
abil
iavnanovax
confer
protect
iav
infect
inbr
mous
model
use
inbr
model
offer
mani
advantag
test
design
vaccin
model
repres
genet
divers
found
human
therefor
order
determin
iavnanovax
could
likewis
confer
protect
outbr
popul
next
vaccin
group
outbr
swisswebst
mice
iavnanovax
group
nonvaccin
mice
includ
control
group
subsequ
challeng
day
post
vaccin
either
lethal
dose
homolog
figur
heterolog
figur
iav
iavnanovax
vaccin
significantli
reducedabl
morbid
weight
loss
figur
penh
figur
f
protect
mortal
figur
e
upon
subsequ
challeng
thu
result
demonstr
iavnanovax
abl
protect
subsequ
homolog
heterolog
iav
infect
translat
outbr
model
present
studi
demonstr
efficaci
administ
cpteg
cph
iavnanovax
produc
iavspecif
immun
respons
provid
protect
subsequ
homolog
heterolog
iav
infect
figur
protect
provid
iavnanovax
figur
iavnanovax
confer
protect
subsequ
homolog
heterolog
iav
infect
outbr
mice
outbr
swiss
webster
mice
receiv
primeboost
vaccin
iavnanovax
without
free
protein
left
unvaccin
fortyf
day
follow
initi
vaccin
mice
challeng
ac
tciu
dose
apuerto
df
tciu
dose
ahong
morbid
mortal
measur
daili
weight
loss
surviv
b
e
c
f
penh
record
daili
measur
lung
function
airway
resist
error
bar
mean
sem
data
repres
one
independ
n
micegroup
c
f
p
p
p
twoway
anova
holmsidak
multiplecomparison
test
b
e
p
p
mantelcox
log
rank
test
found
robust
primeboost
strategi
prime
vaccin
substanti
reduc
morbid
figur
c
complet
prevent
mortal
figur
follow
homolog
iav
challeng
likewis
prime
vaccin
reduc
initi
airway
distress
figur
provid
signific
level
protect
mortal
lethaldos
heterolog
iav
challeng
figur
protect
homolog
heterolog
viru
appear
long
last
iavnanovax
vaccin
also
confer
protect
mice
challeng
day
post
vaccin
figur
iavnanovax
formul
test
herein
contain
iav
ha
np
protein
studi
demonstr
immun
direct
addit
iav
protein
na
enhanc
protect
one
benefit
nanovaccin
platform
abil
easili
plug
play
new
antigen
within
formul
therefor
incorpor
iav
na
protein
within
futur
iavnanovax
formul
may
abl
drive
even
robust
immun
improv
protect
homolog
heterolog
iav
infect
consist
abil
protect
homolog
viru
challeng
intranas
vaccin
iavnanovax
induc
iavspecif
classswitch
gc
b
cell
respons
resid
lung
well
robust
local
igg
iga
system
igg
iavspecif
antibodi
figur
howev
time
point
observ
reduc
iavspecif
igg
iavnanovax
vaccin
mice
compar
iav
infect
day
serum
day
bal
figur
reduct
could
relat
addit
antigen
avail
target
follow
iav
infect
sinc
iavnanovax
contain
iav
ha
np
protein
consist
idea
hai
titer
serum
bal
follow
iavnanovax
similar
observ
iav
infect
well
hai
titer
associ
protect
suggest
haspecif
antibodi
equal
base
observ
protect
abil
trm
iav
recent
suggest
univers
vaccin
iav
induc
cell
respons
order
offer
greatest
level
protect
importantli
analysi
lung
iavnanovax
vaccin
found
presenc
iavspecif
cell
iavspecif
cell
within
lung
parenchyma
base
ivab
exclus
stain
figur
express
marker
consist
canon
tissueresid
memori
phenotyp
lungresid
memori
cell
primarili
identifi
express
follow
infect
vaccin
observ
po
neg
trm
subset
within
lung
iavnanovax
vaccin
mice
unexpectedli
observ
small
proport
po
po
cell
well
figur
c
although
po
po
po
resid
memori
phenotyp
well
character
studi
report
subset
within
skin
role
po
po
cell
may
play
protect
subsequ
iav
infect
remain
determin
previou
studi
shown
mainten
trm
cell
within
lung
nich
influenc
presenc
longev
antigen
depot
follow
iavnanovax
vaccin
observ
presenc
trm
cell
within
lung
day
post
vaccin
number
similar
observ
iav
infect
lung
figur
preliminari
studi
also
suggest
trm
respons
present
lung
least
day
data
shown
prior
studi
shown
nanoparticl
persist
within
lung
day
continu
releas
antigen
nanoparticl
place
tissu
day
follow
vaccin
overal
suggest
iavnanovax
may
act
antigen
depot
similar
observ
iav
infect
may
contribut
upkeep
lungresid
memori
cell
conclus
shown
inocul
polyanhydrid
nanovaccin
encapsul
iav
protein
iavnanovax
provid
protect
homolog
heterolog
iav
infect
protect
associ
induct
gc
b
cell
lung
robust
iavspecif
antibodi
respons
system
local
iavspecif
cell
respons
within
lung
report
demonstr
first
time
vaccin
polyanhydrid
nanoparticl
induc
tissueresid
memori
cell
confer
protect
heterolog
viru
challeng
protect
infect
outbr
popul
altogeth
find
highlight
potenti
util
nanovaccin
platform
vaccin
deliveri
order
induc
system
local
adapt
immun
provid
protect
iav
infect
bn
tw
kl
conceiv
research
zz
tw
kl
design
experi
analyz
data
interpret
result
zz
conduct
experi
eh
provid
technic
assist
process
tissu
sampl
flow
cytometri
kr
jg
bn
manufactur
iavnanovax
zz
kl
wrote
manuscript
zz
kr
jg
tw
bn
kl
edit
manuscript
author
review
approv
manuscript
